To explore potential therapeutic drugs against DNMT3A-mutant AML cells, we elucidated the difference between DNMT3A-mutant and wildtype (wt) AML cells at the transcriptome level. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.